• Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues


MilliporeSigma Expands Verona, Wisconsin, Manufacturing Center

A leading life science company, MilliporeSigma will invest $65 million to expand its facility in Verona, Wisconsin. The company plans to create approximately 50 jobs starting this year.

The new 70,000-square-foot expansion in Verona will allow MilliporeSigma to facilitate complex, large-scale manufacturing of increasingly potent compounds, including Highly Potent Active Pharmaceutical Ingredient (HPAPI) and Antibody-Drug Conjugate (ADC). Both compounds have the potential to treat cancer. The expansion project is slated to break ground this spring and completed by mid-2022.

“ADCs have posted incredible growth over the last decade and regulator agencies’ approval in recent years demonstrate their promise of a targeted therapy,” said Andrew Bulpin, head of Process Solutions at MilliporeSigma. “This investment underscores our commitment to working with innovators to bring new treatments to patients quickly and more efficiently.”

Wisconsin Economic Development Corporation is supporting the project by authorizing up to $200,000 in state income tax credits over the next three years. The actual amount of tax credits MilliporeSigma will receive is contingent upon the number of jobs created.

An economic modeling study estimates the project could generate an additional 43 more jobs in the region, providing more than $182,448 in state income tax revenue annually, according to a release from the WEDC.

“Wisconsin is proud to have innovative and forward-thinking companies like MilliporeSigma develop here,” said Missy Hughes, secretary and CEO of WEDC. “Companies have a choice when deciding to expand, and MilliporeSigma’s decision to invest in Verona is a testament to Wisconsin’s strong business climate and dedicated workforce.”

MilliporeSigma provides contract manufacturing services to pharmaceutical customers, streamlining drug development and production, including pre-clinical and commercial manufacturing services, to reduce quality risk and streamline the process of getting therapies to patients faster. The company has four locations in Wisconsin focused on biochemical production and manufacturing of complex pharmaceutical ingredients.

Exclusive Research